Yon Son Betty Kim, MD, PhD, FRCSC, FAANS
Department of Neurosurgery, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
As a Physician Scientist, Dr. Kim’s laboratory takes a multidisciplinary approach to the research of solid tumors with a specific focus on malignant primary and metastatic brain tumors. Her work has been published in journals such as the New England Journal of Medicine, Nature, Nature Nanotechnology, Nature Biomedical Engineering, Nature Reviews Immunology and Nature Reviews Drug Discovery. Dr. Kim’s lab is interested in understanding the molecular cross-talk that occurs between tumor and stromal cells within the tumor immune-microenvironment, while also developing multiple patented therapeutic strategies to inhibit tumorigenesis. Her current research primarily focuses on finding new ways to promote immune recognition of glioma cells to boost the efficacies of cancer immunotherapies. Her group also pursues the identification of predictive and prognostic biomarkers for personalized medicine in the context of brain tumors.
Education & Training
Degree-Granting Education
| 2002 | McMaster University, Hamilton, CAN, MD, Faculty Medicine |
| 1998 | McGill University, Montreal, CAN, BSc (Hon), Anatomy and Cell Biology |
Postgraduate Training
| 2012-2013 | Clinical Fellowship, Skull Base Surgery, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2012 | Clinical Fellowship, Neurosurgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2012 | FRCSC, Neurologic Surgeon, Royal College of Surgeon, Canada |
| 2006-2009 | Clinician Investigator Program, Neurologic Surgery, University of Toronto, Toronto |
| 2005-2011 | Clinical Residency, Neurosurgery, University of Toronto, Toronto |
Board Certifications
| 2012 | Neurosurgery, Royal College of Physicians and Surgeons, Canada |
| 2002 | Medical Council of Canada/College of Surgeons of Ontario |
Experience & Service
Other Appointments/Responsibilities
Brain SPORE Animal Core Co-Director, UT MD ANDERSON CANCER CENTER Animal Core, HOUSTON, TX, 2020 - Present
Selected Publications
Peer-Reviewed Articles
- Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast. Clin Cancer Res 26(7):1712-1724, 2020. e-Pub 2019. PMID: 31848190.
- von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun 11(1):1508, 2020. e-Pub 2020. PMID: 32198351.
- Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V, Chiang C, Deng W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BYS, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 4(1):69-83, 2020. e-Pub 2019. PMID: 31844155.
- Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19(10):568-586, 2019. e-Pub 2019. PMID: 31462760.
- Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, Zhao H, Wang Y, Jiang W, Kim BYS. Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Adv Sci (Weinh) 6(5):1802070, 2019. e-Pub 2019. PMID: 30886813.
- Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res 25(6):1709-1717, 2019. e-Pub 2018. PMID: 30413527.
- Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
- Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195-203, 2018. e-Pub 2018. PMID: 29332937.
- Lee A, Chan CKF, Seo Ey, Park S, Lu Wj, Hong WX, Kim BYS, Jiang W, Nag D, Lin S, Nguyen P, Weissman IL, Wu JC, Longaker M. Formation of de novo blood vessels by a novel multipotent vessel progenitor cell population for treatment of ischemic injury. Journal of Clinical Investigation, 2018.
- Bi Y, Lee RJ, Wang X, Sun Y, Li L, Wang M, Li C, Xie J, Jiang W, Yang Z, Kim BYS (co-corresponding author), Teng L. Self-Assembled Tumor Penetrable and Reduction Responsive Prodrug by Cell Penetrating Peptide-Bridged SN38-PEG Conjugate for Cancer Chemotherapy. ACS Nano, 2018.
- Yang Z, Shi J, Xie J, Sun J, Chen Y, Liu T, Zhao Y, Zhao X, Wang X, Malkoc V, Chiang C, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Lee A, Jiang W, Teng L, Kim BYS (co-corresponding author), Lee J. Cellular nanoporation releases large quantities of mRNA-encapsulated exosomes for transcriptional manipulation. Nature Biomed Engineering, 2018.
- Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, Kim BYS, Yun K. S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Res 77(19):5360-5373, 2017. e-Pub 2017. PMID: 28807938.
- Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bispecific nanobioconjugate engager for targeted cancer immunotherapy. Nat Nanotechnol 12(8):763-769, 2017. e-Pub 2017. PMID: 28459470.
- Jiang W, Yuan H, Chan CK, von Roemeling CA, Yan Z, Weissman IL, Kim BYS. Lessons from Immuno-Oncology: A New Era for Cancer Nanomedicine. Nat Rev Drug Discov 16(6):369-370, 2017. e-Pub 2017. PMID: 28303024.
- von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends in Biotechnology (Cell Press), 2017.
- Jiang W, von Roemeling C, Qie Y, Chen Y, Liu X, Chen J, Kim BYS. Designing nanomedicine for immune-oncology. Nature Biomedical Engineering, 2017.
- Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BYS. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Scientific Report, 2016.
- Jiang W, Chan CK, Weissman IL, Kim BYS (co-corresponding author), Hahn SM. Immunogenic Priming of Tumor Microenvironment. Trends in Cancer (Cell Press), 2016.
- Jiang W, Huang Y, An Y, Kim BY. Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles. ACS Nano 9(9):8689-96, 2015. e-Pub 2015. PMID: 26212564.
- Kim BYS, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology, 2014.
- Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med 363(25):2434-43, 2010. PMID: 21158659.
- Kim BY, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WC. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Lett 8(11):3887-92, 2008. e-Pub 2008. PMID: 18816147.
- Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3):145-50, 2008. e-Pub 2008. PMID: 18654486.
- Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417(6884):74-8, 2002. PMID: 11986668.